Teva Pharmaceutical Industries Ltd (ADR) (TEVA) was Reiterated by Mizuho to “Buy” while Lowering the Price Target of the company shares to $ 75 from a previous price target of $78 . Mizuho advised their investors in a research report released on May 10, 2016.
Many Wall Street Analysts have commented on Teva Pharmaceutical Industries Ltd (ADR). Shares were Reiterated by Maxim Group on May 9, 2016 to “Buy” and Lowered the Price Target to $ 70 from a previous price target of $74 .Credit Suisse Initiated Teva Pharmaceutical Industries Ltd (ADR) on May 4, 2016 to “Neutral”, Price Target of the shares are set at $60.Company shares were Reiterated by RBC Capital Mkts on Apr 20, 2016 to “Outperform”, Firm has raised the Price Target to $ 75 from a previous price target of $73 .
On the company’s financial health, Teva Pharmaceutical Industries Ltd (ADR) reported $1.20 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on May 9, 2016. Analyst had a consensus of $1.17. The company had revenue of $4810.00 million for the quarter, compared to analysts expectations of $4774.14 million. The company’s revenue was down -3.5 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $1.36 EPS.
Teva Pharmaceutical Industries Ltd (ADR) closed down -3.6 points or -6.68% at $50.27 with 2,53,89,390 shares getting traded on Friday. Post opening the session at $52.21, the shares hit an intraday low of $50 and an intraday high of $52.305 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
Teva Pharmaceutical Industries Limited (Teva) is a global pharmaceutical and drug company. The Company’s generic products cover almost every major therapeutic area. The Company operates its business in two segments: Generic medicines which manufactures and sells generic pharmaceutical products in several dosage forms including tablets capsules injectables inhalants liquids ointments and creams and Specialty medicines which delivers solutions to patients and providers via medicines devices and services. Its Central Nervous System (CNS) portfolio includes Copaxone Azilect and Nuvigil. Its main respiratory medicines include ProAir hydrofluoroalkane QVAR and Duoresp Spiromax. Its oncology portfolio includes Treanda Trisenox Granix Synribo Lonquex Tevagrastim/Ratiograstim Myocet Trisenox and Eporatio. Its women’s health portfolio includes ParaGard Plan B One-Step OTC/Rx (levonorgestrel) and Zoely.